Cite
HARVARD Citation
Halatsch, M. et al. (2019). Bcl‐2/Bcl‐xL inhibition predominantly synergistically enhances the anti‐neoplastic activity of a low‐dose CUSP9 repurposed drug regime against glioblastoma. British journal of pharmacology. pp. 3681-3694. [Online].